Investigating the impact of metabolic disease states on the pharmacodynamics and toxicity of FDA-approved antisense oligonucleotides using an integrated liver-kidney model - anti-sense oligonucleotide…
Active Grant Awarded Last action
- Award ID
- R43TR005374
- Recipient
-
Javelin Biotech Inc. UEI KNL3VGH5KWM5
- Awarding agency
-
National Center for Advancing Translational Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $349,677
Award facts
- Assistance listing
- 93.350 National Center for Advancing Translational Sciences
- Completion date 42% complete
- Originally
- Place of performance
- Woburn, MA 01801, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Center for Advancing Translational Sciences awarded Javelin Biotech Inc. a grant of $349,677 on June 16, 2026, under Assistance Listing 93.350, National Center for Advancing Translational Sciences. The award funds an investigation into how metabolic disease states affect the pharmacodynamics and toxicity of four FDA-approved antisense oligonucleotide (ASO) drugs. Javelin will use its Javelin Liver Tissue Chip Plus (LTC+) platform, which integrates human liver and kidney microphysiological systems, to study distribution, metabolism, excretion, and toxicity profiles, including hepatotoxicity and nephrotoxicity. The full $349,677 is obligated. The period of performance runs from the award date through an ultimate completion date of June 30, 2027, and work is performed in Woburn, MA 01801. The source identifies no sub-recipients for this award. The program's purpose is to reduce costly bottlenecks in the translational research pipeline so new drugs, diagnostics, and medical devices reach patients faster.
Description
Investigating the impact of metabolic disease states on the pharmacodynamics and toxicity of FDA-approved antisense oligonucleotides using an integrated liver-kidney model - anti-sense oligonucleotide (ASO) drugs have shown great potential in the treatment of human diseases. However, the lack of therapeutic efficacy and intolerance of adverse drug reactions (ADRS) and toxicity have led to the termination of numerous ASO candidates in the development pipelines, as well as the discontinuation from the market after approval by the FDA. Hepatotoxicity and nephrotoxicity are two major concerns for the FDA-approved ASO drugs in the market as well as development of new ASO-based therapies. Significant knowledge gaps still exist which prevent US from better understanding the lack of effectiveness and existence of ADRS and toxicity. One of these gaps lies in how an ASO drug goes through absorption, distribution, metabolism, and excretion (ADME) in its target organs and cells. Both in vitro cellular models and in vivo animal models have been used to assess ADME and toxicity of ASO drugs; however, they have numerous limitations. While cellular models lack human complexity, animal models lack human-specificity. Microphysiological systems (MPSS) may provide a solution to overcome this unmet need by providing human specificity and complexity as an in vitro platform. Here, we propose using the javelin liver tissue chip plus (LTC+) platform, which integrates human liver and kidney MPSS, to study distribution, metabolism, excretion, and toxicity profiles (hepato- and nephrotoxicity) of four FDA-approved ASO drugs.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $349,677 |
Quick answers
Who received award R43TR005374?
R43TR005374 was awarded to Javelin Biotech Inc. by National Center for Advancing Translational Sciences (National Institutes of Health) on June 16, 2026.
How much is award R43TR005374 worth?
$349,677 has been obligated on R43TR005374.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award